Boston Immune Technologies and Therapeutics
Russell LaMontagne is the CEO of Boston Immune Technologies and Therapeutics, a biopharmaceutical company developing immune-based approaches for the treatment of cancer and infectious diseases. Russell has 20 years of experience in the health care industry, primarily focusing on consulting roles at biotechnology companies and non-profits from the University of Pennsylvania and the New England Journal of Medicine to VIRxSYS and Bristol-Myers Squibb. Over the past ten years, Russell has organized partnerships with Massachusetts General Hospital to promote clinical trials and new indications for the BCG vaccine. Prior to co-founding Boston Immune Technologies and Therapeutics, Russell served as president of Corinth Group, a boutique healthcare consultancy. Russell received his BS in Biology from the University of Massachusetts at Amherst and his MS from Yale University.